NCT02414412已完成3 期
Immunity Improvement Effect of Ulmus Macrocarpa Water Extract in Adults
适应症
干预措施
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 58
- 主要终点
- serum natural killer cell activity
研究概览
简要总结
This randomized, placebo-controlled, double-blind study evaluates the efficacy and tolerability of Ulmus macrocarpa water extract for immunity improvement in relatively healthy adults. 58 subjects received 500 mg of Ulmus macrocarpa water extract per day or a placebo for 4 weeks.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Supportive Care
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 19 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •subject has peripheral white blood cells between 4,000/Ul and 8,000/Ul
排除标准
- •History of renal disease
- •History of diabetes mellitus
- •History of immune disease
研究组 & 干预措施
Ulmus
Active Comparator
Ulmus macrocarpa water extract 250mg orally 2 times a day for 4 weeks
干预措施: Ulmus macrocarpa water extract (Dietary Supplement)
Placebo
Placebo Comparator
placebo 250mg orally 2 times a day for 4 weeks
干预措施: Ulmus macrocarpa water extract (Dietary Supplement)
结局指标
主要结局
serum natural killer cell activity
时间窗: 1 month
次要结局
- serum interferon-gamma(1 month)
- peripheral white blood cell(1 month)
- serum tumor necrosis factor-alpha level(1 month)
- serum interleukins(1betta, 2,4,8,10, and 12)(1 month)
研究者
Sang Yeoup Lee
professor
Pusan National University Hospital
相似试验
暂停
4 期
Immunomodulatory Effect of Macrolides in Naturally Occurring Influenza Virus Infections in the CommunityInfluenza, HumanNCT03824847The University of Hong Kong100
已完成
2 期
To Investigate the Safety, Pharmacodynamics and Effect on Allergic Reactivity of the Toll-like Receptor 7 (TLR7) Agonist GSK2245035 in Subjects With Respiratory AllergiesMild Asthma and Allergic RhinitisNCT01788813GlaxoSmithKline42
已完成
2 期
A Study on the Immune Response and Safety of a Combined Measles, Mumps, Rubella, Chickenpox Vaccine Compared to a Marketed Combined Vaccine, Given to Healthy Children 4 to 6 Years of AgeMeasles; Mumps; Rubella; ChickenpoxMeaslesNCT05630846GlaxoSmithKline801
已完成
1 期
Safety, Tolerability, Efficacy and Immunogenicity of an Influenza A Vaccine (FP-01.1) in Healthy Volunteers Following Virus ChallengeInfluenza ANCT02071329Immune Targeting Systems Ltd111
已完成
不适用
Ulmus Macrocarpa Hance Extract and Lipid ProfileDyslipidemiasNCT03773315Sang Yeoup Lee80